Clinical Trials Sponsored by Quoin Pharmaceuticals

Total 19804 results

Santhera Pharmaceuticals

Terminated

Phase III Study With Idebenone in Patients With Duchenne Muscular Dystrophy (SIDEROS-E) (SIDEROS-E)

Duchenne Muscular Dystrophy

United States, Belgium, United Kingdom, Austria, France, Germany, Italy, Spain, Switzerland
Avanir Pharmaceuticals

Completed

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease

Alzheimer's Disease | Agitation

United States
Jazz Pharmaceuticals

Completed

A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension

Idiopathic Hypersomnia

France, Spain, United States, Belgium, United Kingdom, Poland, Czechia, Finland
Ferring Pharmaceuticals

Completed

Mesalamine 2 g Sachet for the Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis (UC)

Ulcerative Colitis

Switzerland, Russian Federation, Latvia, United States, Hungary, Ukraine, Serbia, Bulgaria, Canada, Mexico, Poland
Arena Pharmaceuticals

Completed

Tolerability, Pharmacokinetics, and Efficacy of APD371 in Participants With Crohn's Disease Experiencing Abdominal Pain

Abdominal Pain | Crohn's Disease

United States
Modra Pharmaceuticals

Completed

ModraDoc006/r in Patients With Breast Cancer

Metastatic Breast Cancer | Recurrent Breast Cancer

Denmark, Belgium, Spain
Regeneron Pharmaceuticals

Completed

Study to Evaluate an Aflibercept (EYLEA®) Prefilled Syringe

Chorioretinal Vascular Disease

United States
Rigel Pharmaceuticals

Completed

A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA) (SOAR)

Warm Antibody Autoimmune Hemolytic Anemia

United States, Canada
Santhera Pharmaceuticals

Completed

Post Authorisation Safety Study With Raxone in LHON Patients (PAROS)

Leber's Hereditary Optic Neuropathy (LHON)

Italy, Germany, France, Austria, Greece, Netherlands
ASLAN Pharmaceuticals

Completed

A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States, Australia, Singapore
Boston Pharmaceuticals

Completed

Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

Diarrhea-predominant Irritable Bowel Syndrome

United States
Endo Pharmaceuticals

Completed

Safety and Pharmacokinetics of Vasopressin in Healthy Volunteers

Healthy Volunteer Safety Study

United States
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

Homozygous Familial Hypercholesterolemia

United States, Netherlands, Australia, Austria, Canada, France, Greece, Italy, Japan, South Africa, Ukraine
Diasome Pharmaceuticals

Completed

A Single-Blind, Placebo-Controlled, Dose-Ranging Trial of Oral HDV-Insulin in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

United States
Intercept Pharmaceuticals

Completed

Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis (POISE)

Primary Biliary Cirrhosis

United States, Spain, United Kingdom, Austria, Netherlands, Australia, Italy, Germany, Poland, Sweden, France, Canada, Belgium
SymBio Pharmaceuticals

Completed

SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid Tumors

Advanced Solid Tumor

Japan
SymBio Pharmaceuticals

Completed

Drug-Drug Interaction Study of Intravenous Administration of SyB V-1901 and Cyclosporine in Japanese Healthy Subjects

Drug Drug Interaction

Japan
Ferring Pharmaceuticals

Completed

An Open-label Trial Investigating the Efficacy and Safety of a Vaginal Insert in Pregnant Women at Term

Cervical Ripening

Japan
Concert Pharmaceuticals

Completed

Drug-drug Interaction Study of CTP-543 and Itraconazole in Healthy Adult Subjects

Healthy Volunteers

United States
BioCryst Pharmaceuticals

Completed

Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema

Hereditary Angioedema (HAE)

Austria, Denmark, France, Germany, Hungary, Israel, Italy, North Macedonia, Poland, Romania, Switzerland, United Kingdom
Threshold Pharmaceuticals

Terminated

A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma

Metastatic Melanoma

United States, Canada
BioCryst Pharmaceuticals

Completed

Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza

Influenza

United States, South Africa
Inovio Pharmaceuticals

Completed

A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer

Cervical Cancer

United States
CStone Pharmaceuticals

Completed

A Phase I Study of CS1002 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
Jazz Pharmaceuticals

Terminated

A Randomised, Open-label, Three-way Crossover Study to Assess the Pharmacokinetics and Safety of Single Doses of Four Sprays of Sativex® in a Range of Oral pH Environments in Healthy Subjects

Healthy Volunteers
InDex Pharmaceuticals

Completed

The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis (CONDUCT)

Ulcerative Colitis

Hungary, Czechia, France, Germany, Poland, Russian Federation, Serbia, Spain, Sweden, Ukraine
Catabasis Pharmaceuticals

Completed

Study of Edasalonexent With Midazolam and Deflazacort in Healthy Subjects

Healthy

United States
Catabasis Pharmaceuticals

Completed

A 2-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CAT-2054 in Healthy Subjects

Hypercholesterolemia

United States
ASLAN Pharmaceuticals

Terminated

Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC

Biliary Tract Cancer

Taiwan, Korea, Republic of, Singapore
CStone Pharmaceuticals

Completed

A Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors

Solid Tumor, Adult

Australia
Arena Pharmaceuticals

Terminated

Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations

Inflammatory Bowel Diseases | Skin Extra-intestinal Manifestations

Belgium, Germany, Serbia
Regeneron Pharmaceuticals

Completed

Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants

Allergy

United Kingdom, New Zealand, Netherlands, Sweden
Ferring Pharmaceuticals

Completed

A Dose-response Trial Using FE 999049 in Japanese Women Undergoing in Vitro Fertilisation (IVF) / Intracytoplasmic Sperm Injection (ICSI) Treatment

Infertility

Japan
BioCryst Pharmaceuticals

Approved for marketing

Oral Berotralstat Expanded Access Program

Hereditary Angioedema | Prophylaxis | HAE
Boston Pharmaceuticals

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of Repeat Topical Application of BOS-356 in Subjects With Moderate to Severe Acne Vulgaris

Moderate to Severe Acne Vulgaris

United States, Canada
Catabasis Pharmaceuticals

Terminated

An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy (GalaxyDMD)

Duchenne Muscular Dystrophy

United States, Canada, Australia, United Kingdom, Germany, Sweden
Boston Pharmaceuticals

Completed

Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of BOS161721 in Healthy Subjects

Healthy Participants

United States
Boston Pharmaceuticals

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Topical Administration of BOS-475 in Healthy Subjects and Patients With Psoriasis

Psoriasis

Australia
Boston Pharmaceuticals

Completed

Study to Determine the Single and Repeat Dose Pharmacokinetics, Food Effect, Proton Pump Inhibitor (PPI) Drug Interaction, Safety and Tolerability of Oral Prototype Formulations of BOS172767 in Healthy Subjects

Healthy Subjects

United Kingdom
Boston Pharmaceuticals

Completed

Study to Determine the Relative Bioavailability, Single and Repeat Dose Pharmacokinetics, Safety and Tolerability of BOS172767 Enantiomers in Healthy Subjects

Healthy Participants

United Kingdom
Ferring Pharmaceuticals

Completed

A Dose-response Trial Using rFSH FE 999049 in Women Undergoing IVF/ICSI Treatment

Infertility

Belgium, Denmark, Spain, Czechia
Aerie Pharmaceuticals

Completed

Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan

Ocular Hypertension | Open Angle Glaucoma

Japan
Sunesis Pharmaceuticals

Terminated

Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Mantle-Cell Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | Lymphoplasmacytoid Lymphoma

United States
Endo Pharmaceuticals

Completed

Effectiveness and Safety of EN3835 in the Treatment of Cellulite in Women (RELEASE-2)

Edematous Fibrosclerotic Panniculopathy (Cellulite)

United States
Aerie Pharmaceuticals

Completed

Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting

Ocular Hypertension | Glaucoma, Open-Angle

United States
MetiMedi Pharmaceuticals

Unknown

OMT-111 for Terminal Stage Solid Tumors

Breast Cancer | Pancreatic Cancer | Lung Cancer

Vietnam
Processa Pharmaceuticals

Terminated

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

United States
Jazz Pharmaceuticals

Completed

A Post-Marketing Observational Study of VYXEOS™

Therapy-Related Acute Myeloid Leukemia | Acute Myeloid Leukemia With Myelodysplasia-Related Changes

United States
CVI Pharmaceuticals

Unknown

Safety and Efficacy of CVI-LM001 in Patients With Hypercholesterolemia

Hyperlipidemia

China
Jazz Pharmaceuticals

Approved for marketing

A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USA

Small Cell Lung Cancer

3

Subscribe